回顾与思考——丙型肝炎防治研究三十年

丙型肝炎的防治研究约有三十余年,取得了辉煌成果：HCV的发现和证明创造了人类发现新生命的先河;重视HCV分子生物学、感染免疫及发病机制等基础研究,是传染病学研究的基本规律;聚乙二醇干扰素联合利巴韦林标准化抗病毒治疗获得成功,尤其对中国人持续病毒学应答率高达80%以上,是细胞因子成功临床应用的典范;直接抗病毒药物或联合应用使临床治愈所有丙型肝炎患者成为可能,这是一个最成功的借鉴;持续病毒感染并在一定条件下维持免疫稳态是机体与病毒相互作用的结果,丙型肝炎疫苗研究还将继续。...

Full description

Saved in:
Bibliographic Details
Published in临床肝胆病杂志 Vol. 31; no. 11; pp. 1803 - 1806
Main Author 贾战生
Format Journal Article
LanguageChinese
Published 中国人民解放军第四军医大学唐都医院传染科,西安,710038 2015
Subjects
抗病毒药
病毒性肝炎疫苗
肝炎,丙型
肝炎,丙型
病毒性肝炎疫苗
抗病毒药
Online AccessGet full text
ISSN1001-5256
DOI10.3969/j.issn.1001-5256.2015.11.009

Cover

More Information
Summary:丙型肝炎的防治研究约有三十余年,取得了辉煌成果：HCV的发现和证明创造了人类发现新生命的先河;重视HCV分子生物学、感染免疫及发病机制等基础研究,是传染病学研究的基本规律;聚乙二醇干扰素联合利巴韦林标准化抗病毒治疗获得成功,尤其对中国人持续病毒学应答率高达80%以上,是细胞因子成功临床应用的典范;直接抗病毒药物或联合应用使临床治愈所有丙型肝炎患者成为可能,这是一个最成功的借鉴;持续病毒感染并在一定条件下维持免疫稳态是机体与病毒相互作用的结果,丙型肝炎疫苗研究还将继续。
Bibliography:hepatitis C ; antiviral agents ; viral hepatitis vaccines
JIA Zhansheng. （ Centre of Diagnosis and Treatment for Infectious Diseases of Chinese PLA, Tangdu Hospital, Fourth Military Medical Univer- sity, Xi＇an 710038, China）
The research on prophylaxis and treatment of hepatitis C has been performed for more than 30 years, with outstanding achieve- ments. The discovery and confirmation of hepatitis C virus （HCV） was a milestone for how humans discovered new life. Emphasis on HCV molecular biology, infection immunity, and pathogenesis is the basic rule for scientific research on infectious diseases. PEG - IFN combined with ribavirin as the standardized antiviral treatment has been a great success; this combination therapy achieves a sustained viral response more than 80% in Chinese people, which is a typical example for successful clinical application of cytokines. Direct - acting antiviral agent （DAA） or combined application has made it possible to cure all patients infected with hepatitis C, which is the most
ISSN:1001-5256
DOI:10.3969/j.issn.1001-5256.2015.11.009